Olanzapine and haloperidol in first episode psychosis: two-year data.
about
Antipsychotic medication for early episode schizophreniaEfficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysisPharmacologic treatment of schizophreniaCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewEffects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsChange in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychoticsAtypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.A positive association between homeostasis model assessment of insulin resistance score and the Trp64Arg polymorphism of the β3-Adrenergic receptor gene in schizophrenia patients in Taiwan.Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patientsWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Metabolic effects of olanzapine in patients with newly diagnosed psychosis.Aripiprazole versus haloperidol treatment in early-stage schizophrenia.Quantifying clinical relevance in the treatment of schizophrenia.Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychoticsTeaching trainees to negotiate research collaborations with industry: a mentorship model.Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment.Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review.Effect of antipsychotic medications on glucose and lipid levels.Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons.Early intervention in schizophrenia in developing countries: focus on duration of untreated psychosis and remission as a treatment goal.Second-generation antipsychotic discontinuation in first episode psychosis: an updated review.Guidelines for the Pharmacotherapy of Schizophrenia in Adults.Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention.Imaging mental disorders in the 21st century.Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats.Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting.Predictors of symptomatic remission in first-episode psychosis outpatients treated with quetiapine: a naturalistic study.Olanzapine: review of safety 2008Translation and cultural adaptation of Glasgow Antipsychotic Side-effects Scale (GASS) in ArabicTardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
P2860
Q24236683-A3496F51-A30A-4285-AD59-04A4159EDF79Q24603049-1A9DC0BA-45CE-4EF4-B4A3-573FF46A2B5AQ24604457-7304C7C5-983C-4F10-93D8-852A667787BBQ28079821-A4920CF5-2A73-47AC-B240-C80F4C438B49Q33503890-C8AAD120-9021-44D9-9339-9F86405944AEQ33533853-1CCBF23A-25B1-48F0-8E9B-1CE4377FF057Q33566124-23DFC35C-622B-4A87-97A8-FA0E39BB5BDEQ33903511-36D3871A-0B15-4CC9-9E55-87EBA2F67CEEQ34117015-0A2E1A30-370C-4C8D-A1E3-D0CDF1FE61BEQ34277168-F75CE607-A4B1-48F4-A35A-FEE6295C0A17Q34315836-4C0DEA8F-4EEA-4914-B2F5-4C5CA916D67CQ34318126-9C71E3A1-3FB1-4BDD-8C25-CA3A1DB721D1Q34329829-537F71CF-019B-4D09-AEF3-F63B5A69990BQ34640811-02958C7C-FD38-4679-9756-10CC62D44B04Q35323981-CF1EE5BF-BEE5-4334-9540-AB8879641C82Q35684487-D608E5EC-2665-477C-805A-2DB18FE13468Q35819467-68FCAD76-9896-4FD3-A688-31613B6224A3Q35873789-5810F640-1946-400D-B13E-63AC4A1BFE46Q35920534-6FB4CBBB-31C4-4AE3-852A-DA1793FA5A6EQ36580637-33BBD777-2CFC-4F59-8115-E2B7CD283C18Q36621075-34322ED0-65A7-4E2D-BF64-066AF9F3F6D2Q37322658-CB583D1F-12E5-497E-85B7-BE0E65F4CA37Q37735606-55941C5D-B548-46DC-A693-4311DE395CC3Q37865505-9E5026BA-FE7A-4954-A175-1E6D4BD83CAEQ37953186-491DE37A-7308-4781-9B37-52886CA12D24Q38051437-F49788AF-3072-46C0-9609-8829A32834A8Q38083513-AAE4F488-B0B5-4886-BC8E-81DBFC59CAD4Q39432209-246BE4ED-9E99-48A9-B925-824F744C7650Q42608128-1C8F2434-C3AB-4370-8A0D-B19863D40DA0Q42688877-F34FB0EF-B6F8-4758-98F2-79AAB89A7A35Q42692847-F09F9962-C6B4-464E-8CFE-51195872BBBEQ43737302-8A0FC1E4-132A-4BB5-9BCF-87261AC88165Q46604957-066174E7-C4AF-490D-B406-287199A9DD40Q46798743-C01DEFAF-E59C-4BE8-91F0-84728B118AE6Q47707388-2B40D360-8E87-4CE7-9833-2D6DDD5E49E7Q48081253-260BE701-90B5-4EDC-9A88-A35BB3D2DE1DQ53892275-BEF1E16F-FBD2-4B64-8D7D-7696E3D9657DQ56791028-701EAD60-7B16-4A7A-8FAB-A73B43E6DD2EQ58715936-E1923B40-90B6-4857-B1DD-7074A1337C7CQ58760344-709E7900-8BEB-4CC4-8159-D1900174CF58
P2860
Olanzapine and haloperidol in first episode psychosis: two-year data.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Olanzapine and haloperidol in first episode psychosis: two-year data.
@ast
Olanzapine and haloperidol in first episode psychosis: two-year data.
@en
type
label
Olanzapine and haloperidol in first episode psychosis: two-year data.
@ast
Olanzapine and haloperidol in first episode psychosis: two-year data.
@en
prefLabel
Olanzapine and haloperidol in first episode psychosis: two-year data.
@ast
Olanzapine and haloperidol in first episode psychosis: two-year data.
@en
P2093
P1476
Olanzapine and haloperidol in first episode psychosis: two-year data.
@en
P2093
A J Rothschild
D O Perkins
HGDH Study Group
J A Lieberman
J P McEvoy
R B Zipursky
P304
P356
10.1016/J.SCHRES.2006.06.021
P407
P577
2006-08-02T00:00:00Z